Famitinib

Lung Cancer

Hansoh BioMedical R&D CompanySmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Carboplatin SystImmune Inc.	Phase 4	BB
CIS-DIAMMINEDICHLOROPLATINUM II University of Vermont	Phase 4	BB
PROPOFOL Kaohsiung Medical University Chung-Ho Memorial Hospital	Phase 4	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Famitinib is also rated in:

triple-negative breast carcinomaDormant

BB

Indicative ·

68 / 100

breast carcinomaDormant

BB

Indicative ·

66 / 100

EGFR Activating MutationDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.